Loading...
XNASBCPC
Market cap5.43bUSD
Dec 24, Last price  
167.17USD
1D
1.11%
1Q
-3.78%
Jan 2017
99.20%
Name

Balchem Corp

Chart & Performance

D1W1MN
XNAS:BCPC chart
P/E
50.07
P/S
5.89
EPS
3.34
Div Yield, %
0.42%
Shrs. gr., 5y
—
Rev. gr., 5y
7.46%
Revenues
922m
-2.11%
67,406,000839,095,000100,905,000176,201,000232,050,000219,438,000255,071,000291,867,000310,393,000337,173,000541,383,000552,492,000553,204,000594,790,000643,679,000643,705,000703,644,000799,023,000942,358,000922,439,000
Net income
109m
+3.01%
8,026,00010,954,00012,278,00016,118,00019,050,00026,785,00033,277,00038,765,00040,005,00044,874,00052,826,00059,722,00055,972,00090,071,00078,573,00079,671,00084,623,00096,104,000105,367,000108,543,000
CFO
184m
+32.64%
12,145,00013,698,00016,370,00015,637,00022,897,00048,072,00039,030,00044,902,00053,781,00055,692,00085,350,000103,826,000107,612,000110,618,000118,697,000124,461,000150,494,000160,514,000138,536,000183,761,000
Dividend
Dec 26, 20230.79 USD/sh
Earnings
Feb 14, 2025

Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. The company sells its products through sales force, independent distributors, and sales agents. Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.
URL
https://balchem.com/
IPO date
Jun 03, 1986
Employees
1,284
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
922,439
-2.11%
942,358
17.94%
799,023
13.56%
Cost of revenue
765,563
797,172
671,521
Unusual Expense (Income)
NOPBT
156,876
145,186
127,502
NOPBT Margin
17.01%
15.41%
15.96%
Operating Taxes
28,718
28,382
29,129
Tax Rate
18.31%
19.55%
22.85%
NOPAT
128,158
116,804
98,373
Net income
108,543
3.01%
105,367
9.64%
96,104
13.57%
Dividends
(22,872)
(20,713)
(18,723)
Dividend yield
0.47%
0.52%
0.34%
Proceeds from repurchase of equity
(4,469)
(32,211)
(28,296)
BB yield
0.09%
0.81%
0.51%
Debt
Debt current
8,442
4,022
2,361
Long-term debt
346,878
460,610
118,044
Deferred revenue
2,658
Other long-term liabilities
68,623
42,833
20,826
Net debt
286,797
393,777
63,621
Cash flow
Cash from operating activities
183,761
138,536
160,514
CAPEX
(37,892)
(50,290)
(37,449)
Cash from investing activities
(34,813)
(416,014)
(35,300)
Cash from financing activities
(153,321)
246,679
(102,178)
FCF
141,552
17,151
100,748
Balance
Cash
64,447
66,560
103,239
Long term investments
4,076
4,295
(46,455)
Excess cash
22,401
23,737
16,833
Stockholders' equity
908,331
809,478
729,299
Invested Capital
1,434,761
1,399,691
993,262
ROIC
9.04%
9.76%
9.78%
ROCE
10.77%
9.77%
12.07%
EV
Common stock shares outstanding
32,448
32,393
32,672
Price
148.75
21.82%
122.11
-27.57%
168.60
46.33%
Market cap
4,826,640
22.02%
3,955,509
-28.19%
5,508,499
47.09%
EV
5,113,437
4,349,286
5,572,120
EBITDA
211,811
197,034
176,381
EV/EBITDA
24.14
22.07
31.59
Interest
22,613
10,268
2,456
Interest/NOPBT
14.41%
7.07%
1.93%